NEOGAP Therapeutics AB

NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company founded in 2016 by Dr. Hans Grönlund. Located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden, the company's slogan "Science for cure" reflects its main focus on immuno-oncology. NEOGAP's vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. The company's mission is to become an important player in the battle against cancer by the development and commercialization of innovative cancer immunotherapy. The company operates in the Biotechnology, Health Care, and Pharmaceutical industries, with its headquarters based in Sweden. NEOGAP Therapeutics AB secured a kr5.00MGrant investment on 26 March 2024 from Eurostars. The company's commitment to leveraging immunotherapy to improve cancer treatment, combined with its recent investment, signifies its potential for growth and innovation in the cancer treatment space. With a clear mission and strategic location within the biopharmaceutical hub in Stockholm, NEOGAP Therapeutics AB presents a promising investment opportunity for venture capitalists seeking to support cutting-edge advancements in oncology treatment.